EntryPoint Capital LLC Acquires Shares of 191,429 Autolus Therapeutics plc (NASDAQ:AUTL)

EntryPoint Capital LLC bought a new position in shares of Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 191,429 shares of the company's stock, valued at approximately $450,000. EntryPoint Capital LLC owned 0.07% of Autolus Therapeutics at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of AUTL. Dumont & Blake Investment Advisors LLC bought a new position in shares of Autolus Therapeutics during the fourth quarter valued at $35,000. Arkadios Wealth Advisors acquired a new position in Autolus Therapeutics in the fourth quarter valued at about $47,000. Capstone Investment Advisors LLC bought a new stake in Autolus Therapeutics during the third quarter worth about $51,000. Daiwa Securities Group Inc. raised its position in shares of Autolus Therapeutics by 55.5% during the fourth quarter. Daiwa Securities Group Inc. now owns 23,743 shares of the company's stock worth $56,000 after acquiring an additional 8,479 shares during the last quarter. Finally, Avanza Fonder AB acquired a new position in shares of Autolus Therapeutics during the fourth quarter valued at $75,000. Institutional investors and hedge funds own 72.83% of the company's stock.

Autolus Therapeutics Price Performance

NASDAQ AUTL traded up $0.01 during trading on Friday, reaching $1.66. 697,449 shares of the company's stock were exchanged, compared to its average volume of 1,396,227. The business has a 50 day moving average price of $1.96 and a 200-day moving average price of $2.82. The stock has a market capitalization of $441.72 million, a P/E ratio of -1.37 and a beta of 2.07. Autolus Therapeutics plc has a fifty-two week low of $1.56 and a fifty-two week high of $6.31.

Remove Ads

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last posted its earnings results on Thursday, March 20th. The company reported ($0.09) earnings per share for the quarter, topping analysts' consensus estimates of ($0.21) by $0.12. The business had revenue of $0.03 million for the quarter, compared to analyst estimates of $2.98 million. On average, analysts forecast that Autolus Therapeutics plc will post -0.94 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have issued reports on AUTL shares. Wells Fargo & Company reduced their price objective on shares of Autolus Therapeutics from $8.00 to $6.00 and set an "overweight" rating on the stock in a research note on Friday, March 21st. Needham & Company LLC restated a "buy" rating and issued a $10.00 price target on shares of Autolus Therapeutics in a research report on Monday, January 13th. Six analysts have rated the stock with a buy rating, According to MarketBeat, Autolus Therapeutics has an average rating of "Buy" and an average price target of $9.52.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.